news
Roche and Polyphor join efforts to combat multi-drug-resistant bacterial infections
4 November 2013 | By Roche
Roche will make an upfront payment of CHF 35 million to Polyphor as well as payments upon reaching certain development...
List view / Grid view
Roche
news
Roche and Chugai’s investigational RoActemra® (tocilizumab) subcutaneous formulation shows comparable long-term efficacy and tolerability to the intravenous formulation in rheumatoid arthritis
26 October 2013 | By Just:: Health Communications
“These data show that RoActemra can continue to deliver meaningful improvements for people living with rheumatoid arthritis..."
article
PCR In-Depth Focus 2013
In this PCR In-Depth Focus: Challenges for qRT-PCR in detecting / quantifying microRNA in vitro and in vivo; Emerging clinical applications of digital PCR; Workshop Preview: Advanced 3d cell based assays, preparation, analysis and troubleshooting...
news
Roche to invest 800 million Swiss francs in global biologic medicine manufacturing network
14 October 2013 | By Roche
Investment to help meet rising demand for licensed biologics and expected pipeline growth...
news
Roche inaugurates translational and Clinical Research Center at the Alexandria Center for life science in New York City
1 October 2013 | By Roche
Leading scientists join together to discuss breakthrough research that addresses serious medical needs...
news
Data show Roche’s new subcutaneous form of Herceptin is preferred by patients and could save resources in Europe’s hospitals
30 September 2013 | By Roche
Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients...
news
Roche’s Kadcyla helped people with advanced HER2-positive breast cancer live longer without their disease worsening in new phase III study
28 September 2013 | By Roche
Kadcyla nearly doubled the time that patients lived without their disease worsening compared with treatment of physician’s choice...
news
Roche to share important oncology data at European Cancer Congress (ECC)
23 September 2013 | By Roche
Data for established therapies Avastin, Herceptin, Kadcyla and Zelboraf amongst highlights...
news
Christoph Franz nominated to become new Roche Chairman
16 September 2013 | By Roche
At the forthcoming Annual Shareholders Meeting on 4 March 2014, the Roche Board of Directors will propose Christoph Franz to be elected as Chairman of the Board.
news
Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
2 September 2013 | By Roche
Roche announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission...
news
FT Global Pharmaceutical and Biotechnology Conference
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
news
Roche and the Medicines Patent Pool sign agreement to increase access to medicines to treat CMV infection in HIV-patients, a major cause of blindness
5 August 2013 | By Roche
The Medicines Patent Pool and Roche announce an agreement...
news
Roche’s obinutuzumab (GA101) delayed disease progression longer than MabThera/Rituxan in people with one of the most common forms of blood cancer
24 July 2013 | By Roche
Results from the phase III CLL11 study...
news
“Roche Continents” at the Salzburg Festival explores the common ground of creativity in art and science
22 July 2013 | By Roche
Roche invites 100 students from all over Europe to the Salzburg Festival...
news
Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
19 July 2013 | By Roche
Tests support long-term routine management of organ transplant recipients...
